Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
AbbVie Inc. (NYSE: ABBV) shares increased 0.74 percent to close at $45.04 a share Monday. The stock traded between $44.39 and $45.20 on volume of 3.83 million shares traded. Analysts at Argus have recently initiated coverage on the company with a “buy” rating. Shares of AbbVie have gained approximately 31.0 percent year-to-date.
Find out more about AbbVie including full access to the free equity report at:
Impax Laboratories Inc. (NASDAQ: IPXL) shares declined 1.79 percent to close at $21.35 a share Monday. The stock traded between $21.10 and $22.01 on volume of 775,557 shares traded. Analysts at Buckingham have recently downgraded the company’s rating to “underperform” from “neutral”. Shares of Impax Laboratories have gained approximately 50.0 percent year-to-date.
Find out more about Impax Laboratories including full access to the free equity report at:
Oncomed Pharmaceuticals Inc. (NASDAQ: OMED) shares declined 2.42 percent to close at $19.36 a share Monday. The stock traded between $19.00 and $20.24 on volume of 207,993 shares traded. Analysts at Leerink have recently initiated coverage on the company with an “outperform” rating and a price target of $27.00. Shares of Oncomed Pharmaceuticals have fallen approximately 28.0 percent year-to-date.
Find out more about Oncomed Pharmaceuticals including full access to the free equity report at:
XOMA Corp. (NASDAQ: XOMA) shares declined 3.73 percent to close at $3.87 a share Monday. The stock traded between $3.87 and $4.14 on volume of 1.17 million shares traded. Analysts at Piper Jaffray have recently initiated coverage on the company with an “overweight” rating and a price target of $8.00.
Find out more about XOMA including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...